Xenetic Biosciences Q4 EPS $0.77 Beats $(0.87) Estimate, Sales $671.96K Miss $680.00K Estimate
Portfolio Pulse from Happy Mohamed
Xenetic Biosciences (NASDAQ:XBIO) reported Q4 earnings of $0.77 per share, surpassing the $(0.87) estimate, marking a 177% increase from last year. However, their Q4 sales of $671.96K missed the $680.00K estimate, though it's a 37.99% increase from the previous year.
March 22, 2024 | 12:03 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Xenetic Biosciences reported a significant beat on Q4 EPS estimates but slightly missed sales forecasts. The EPS was $0.77, beating the $(0.87) estimate, and sales were $671.96K, missing the $680K estimate.
The significant beat on the EPS estimate, despite the slight miss on sales forecasts, indicates strong financial performance and operational efficiency. This positive earnings report, especially the substantial increase in EPS year-over-year, is likely to instill investor confidence and could lead to a short-term positive impact on XBIO's stock price.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100